Tempest Therapeutics (NASDAQ:TPST) versus X4 Pharmaceuticals (NASDAQ:XFOR) Head-To-Head Review

Tempest Therapeutics (NASDAQ:TPST) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.

Profitability

This table compares Tempest Therapeutics and X4 Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-576.56%	-134.99%
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%

Volatility & Risk

Tempest Therapeutics has a beta of -1.72, meaning that its stock price is 272% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.

Insider & Institutional Ownership

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 36.2% of Tempest Therapeutics shares are held by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Tempest Therapeutics and X4 Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26 million	($4.28)	-0.25
X4 Pharmaceuticals	$15.85 million	25.28	-$79.20 million	($1.20)	-3.37

Tempest Therapeutics has higher earnings, but lower revenue than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Tempest Therapeutics and X4 Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1	1	0	0	1.50
X4 Pharmaceuticals	1	1	4	0	2.50

X4 Pharmaceuticals has a consensus price target of $11.25, indicating a potential upside of 178.47%. Given X4 Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Tempest Therapeutics.

Summary

X4 Pharmaceuticals beats Tempest Therapeutics on 9 of the 13 factors compared between the two stocks.

About Tempest Therapeutics

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.